Smith & Nephew (SN) Competitors

GBX 979
-5.00 (-0.51%)
(As of 04/30/2024 ET)

SN vs. CTEC, HIK, HCM, HLN, MXCT, NIOX, EKF, CREO, NCYT, and IUG

Should you be buying Smith & Nephew stock or one of its competitors? The main competitors of Smith & Nephew include ConvaTec Group (CTEC), Hikma Pharmaceuticals (HIK), HUTCHMED (HCM), Haleon (HLN), MaxCyte (MXCT), NIOX Group (NIOX), EKF Diagnostics (EKF), Creo Medical Group (CREO), Novacyt (NCYT), and Intelligent Ultrasound Group (IUG). These companies are all part of the "medical" sector.

Smith & Nephew vs.

Smith & Nephew (LON:SN) and ConvaTec Group (LON:CTEC) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, community ranking, earnings, valuation and analyst recommendations.

In the previous week, Smith & Nephew had 1 more articles in the media than ConvaTec Group. MarketBeat recorded 2 mentions for Smith & Nephew and 1 mentions for ConvaTec Group. ConvaTec Group's average media sentiment score of 1.34 beat Smith & Nephew's score of 0.00 indicating that ConvaTec Group is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Smith & Nephew
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
ConvaTec Group
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Smith & Nephew has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Comparatively, ConvaTec Group has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500.

55.6% of Smith & Nephew shares are owned by institutional investors. Comparatively, 66.7% of ConvaTec Group shares are owned by institutional investors. 0.2% of Smith & Nephew shares are owned by company insiders. Comparatively, 20.2% of ConvaTec Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

ConvaTec Group has a net margin of 6.08% compared to Smith & Nephew's net margin of 4.74%. ConvaTec Group's return on equity of 7.89% beat Smith & Nephew's return on equity.

Company Net Margins Return on Equity Return on Assets
Smith & Nephew4.74% 5.02% 4.27%
ConvaTec Group 6.08%7.89%4.79%

Smith & Nephew has higher revenue and earnings than ConvaTec Group. Smith & Nephew is trading at a lower price-to-earnings ratio than ConvaTec Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smith & Nephew£5.55B1.54£263M£0.244,079.17
ConvaTec Group£2.14B2.36£130.30M£0.054,920.00

Smith & Nephew pays an annual dividend of GBX 30 per share and has a dividend yield of 3.1%. ConvaTec Group pays an annual dividend of GBX 5 per share and has a dividend yield of 2.0%. Smith & Nephew pays out 12,500.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. ConvaTec Group pays out 10,000.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Smith & Nephew currently has a consensus target price of GBX 1,362.50, suggesting a potential upside of 39.17%. ConvaTec Group has a consensus target price of GBX 307.17, suggesting a potential upside of 24.86%. Given Smith & Nephew's higher possible upside, equities analysts clearly believe Smith & Nephew is more favorable than ConvaTec Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Smith & Nephew
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
ConvaTec Group
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00

Smith & Nephew received 202 more outperform votes than ConvaTec Group when rated by MarketBeat users. However, 66.54% of users gave ConvaTec Group an outperform vote while only 61.83% of users gave Smith & Nephew an outperform vote.

CompanyUnderperformOutperform
Smith & NephewOutperform Votes
554
61.83%
Underperform Votes
342
38.17%
ConvaTec GroupOutperform Votes
352
66.54%
Underperform Votes
177
33.46%

Summary

ConvaTec Group beats Smith & Nephew on 13 of the 20 factors compared between the two stocks.

Get Smith & Nephew News Delivered to You Automatically

Sign up to receive the latest news and ratings for SN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SN vs. The Competition

MetricSmith & NephewMedical Devices IndustryMedical SectorLON Exchange
Market Cap£8.56B£2.99B£4.87B£1.40B
Dividend Yield3.13%2.53%2.85%11.99%
P/E Ratio4,079.17215.79196.791,740.08
Price / Sales1.54194.792,394.90346,559.17
Price / Cash18.6816.5446.4932.80
Price / Book1.644.344.722.55
Net Income£263M£52.05M£102.40M£179.87M
7 Day Performance-0.59%-2.10%1.38%0.59%
1 Month PerformanceN/A-3.84%-5.95%4.13%
1 Year Performance-25.52%43.97%4.54%16.79%

Smith & Nephew Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CTEC
ConvaTec Group
1.7068 of 5 stars
GBX 250
-1.3%
GBX 307.17
+22.9%
+13.7%£5.13B£2.14B5,000.0010,136News Coverage
HIK
Hikma Pharmaceuticals
0.6276 of 5 stars
GBX 1,924
-0.3%
GBX 2,068.75
+7.5%
+4.5%£4.27B£2.88B2,829.419,100News Coverage
HCM
HUTCHMED
0 of 5 stars
GBX 297.50
-2.1%
N/A+18.3%£2.54B£838M2,975.001,988
HLN
Haleon
0.2728 of 5 stars
GBX 339.50
+2.5%
GBX 356
+4.9%
-3.3%£31.00B£11.30B3,086.3625,408News Coverage
MXCT
MaxCyte
0 of 5 stars
GBX 295
flat
N/A-24.4%£307.18M£41.29M-1,017.24143
NIOX
NIOX Group
0.189 of 5 stars
GBX 71
+1.4%
GBX 77
+8.5%
+53.7%£300.15M£36.80M3,550.0092Gap Up
EKF
EKF Diagnostics
0 of 5 stars
GBX 28.80
+2.7%
N/A+2.9%£130.67M£52.61M2,880.00356Gap Up
CREO
Creo Medical Group
0 of 5 stars
GBX 36
flat
N/A+46.9%£130.13M£29.27M-327.27279Gap Up
NCYT
Novacyt
0 of 5 stars
GBX 72
+2.6%
N/A+44.9%£50.85M£7.87M-200.00120Gap Up
High Trading Volume
IUG
Intelligent Ultrasound Group
0 of 5 stars
GBX 8.75
+4.9%
N/A-44.6%£28.60M£10.26M-875.0065News Coverage
Gap Up

Related Companies and Tools

This page (LON:SN) was last updated on 5/1/2024 by MarketBeat.com Staff

From Our Partners